CCM
ALXN

Chilton Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Chilton Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-31,005
Closed -$3.62M – 169
2016
Q2 		$3.62M Buy
31,005
+15,615
+101% +$2.22M 0.35% 76
2016
Q1 		$2.14M Sell
15,390
-18,815
-55% -$2.76M 0.21% 89
2015
Q4 		$6.53M Buy
+34,205
New +$5.98M 0.68% 61

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Chilton Capital Management's ALXN Position: Q3 2016 in Review

Chilton Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 31,005 shares — an estimated $3.62M sold.

Chilton Capital Management first reported a position in ALXN in Q4 2015 and held it in 3 quarters. The position peaked at $6.53M in Q4 2015. 517 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

  • Chilton Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Chilton Capital Management sold 31,005 Alexion Pharmaceuticals shares in Q3 2016, an estimated $3.62M.
  • Chilton Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 3 quarters.
  • Chilton Capital Management's Alexion Pharmaceuticals position peaked at $6.53M in Q4 2015.
  • 517 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Chilton Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.